ASTS
AST SpaceMobile, Inc.
ASTS lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to grow, though they disagree widely on how much.
CHRN
ChronoScale Corporation
There isn't enough reported data to score CHRN yet.
ASTS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
ASTS's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
CHRN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
CHRN's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
ASTS PE Valuation
ASTS has no meaningful PE right now: it lost money over the past year.
CHRN PE Valuation
CHRN has no meaningful PE right now: it lost money over the past year.
ASTS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ASTS's losses to grow, with revenue growing. However, they disagree widely on these estimates.
CHRN Forward outlook
There aren't enough analyst estimates for CHRN to show an outlook.
ASTS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.15 | -$0.91 |
| Q2 2026 | -$2.16 | -$0.27 |
| Q1 2026 | -$1.80 | +$0.19 |
| Q4 2025 | -$1.34 | +$0.61 |
| Q3 2025 | -$1.24 | +$0.88 |
| Q2 2025 | -$1.89 | -$0.64 |
| Q1 2025 | -$1.99 | -$1.01 |
| Q4 2022 | -$0.58 | -$0.21 |
CHRN has the stronger earnings trend. Trailing diluted EPS is down 273% for ASTS versus CHRN down 194%.
CHRN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2026 | -$6.83 | +$0.40 |
| Q4 2025 | -$6.59 | +$1.84 |
| Q3 2025 | -$5.56 | +$4.19 |
| Q2 2025 | -$6.52 | +$5.33 |
| Q1 2025 | -$7.23 | +$7.32 |
| Q4 2024 | -$8.43 | +$8.07 |
| Q3 2024 | -$9.75 | +$7.05 |
| Q2 2024 | -$11.85 | +$6.30 |
CHRN is still losing money, but far less than before: $6.83 per share over the past year, against $47.25 at its worst in late 2019.
ASTS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $42.3M | +187% |
| Q2 2026 | $31.5M | +2627% |
| Q1 2026 | $14.7M | +1952% |
| Q4 2025 | $54.3M | +2731% |
| Q3 2025 | $14.7M | +1240% |
| Q2 2025 | $1.2M | +28% |
| Q1 2025 | $718K | +44% |
| Q3 2022 | $4.2M | +70% |
ASTS has the edge over CHRN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -415% | +694 points |
| Q2 2026 | -948% | +10744 points |
| Q1 2026 | -1686% | +7083 points |
| Q4 2025 | -175% | +2446 points |
| Q3 2025 | -1109% | +4850 points |
| Q2 2025 | -11692% | -4693 points |
| Q1 2025 | -8769% | +2331 points |
| Q4 2024 | -2621% | N/A |
ASTS's operating margin was −415% last quarter, up 694 points from the same quarter a year ago.
CHRN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $41.5M | +881% |
| Q1 2026 | $2.1M | -37% |
| Q4 2025 | $3.1M | -38% |
| Q3 2025 | $4.2M | +2.4% |
| Q2 2025 | $2.1M | -58% |
| Q1 2025 | $3.4M | -10% |
| Q4 2024 | $5.1M | +5% |
| Q3 2024 | $4.1M | -10% |
CHRN's revenue is growing: $41M last quarter, up 1917% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -60% | +133 points |
| Q1 2026 | -262% | -161 points |
| Q4 2025 | -144% | -100 points |
| Q3 2025 | -33% | +31 points |
| Q2 2025 | -193% | -146 points |
| Q1 2025 | -102% | -15 points |
| Q4 2024 | -44% | +27 points |
| Q3 2024 | -64% | -0.3 points |
CHRN has the edge over ASTS on profitability, with a higher operating margin.
ASTS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$464.2M | -$161.4M |
| Q2 2026 | -$694.8M | -$341.1M |
| Q1 2026 | -$309.7M | -$160.7M |
| Q4 2025 | -$330.7M | -$220.3M |
| Q3 2025 | -$302.9M | -$239.1M |
| Q2 2025 | -$353.6M | -$315.3M |
| Q1 2025 | -$149M | -$61.3M |
| Q4 2024 | -$110.5M | -$63.2M |
ASTS has burned cash in almost every quarter: −$1.8B over the past year, against −$916M the year before.
CHRN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $11.6M | +$13.6M |
| Q1 2026 | -$2.1M | -$148K |
| Q4 2025 | -$4.5M | -$3M |
| Q3 2025 | -$2.1M | +$212K |
| Q2 2025 | -$3.5M | -$814K |
| Q1 2025 | -$2M | +$1.5M |
| Q4 2024 | -$1.5M | +$173K |
| Q3 2024 | -$2.3M | +$1.1M |
CHRN has the edge over ASTS on cash generation, producing positive trailing cash flow while its opponent burns cash.
ASTS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +1.1M shares |
| 1 year | +10% | +27.3M shares |
| 3 years | +235% | +211M shares |
| 5 years | +480% | +248M shares |
| Available history | +944% | +271M shares |
ASTS has the edge over CHRN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
CHRN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3981% | +142M shares |
| 1 year | +8489% | +144M shares |
| 3 years | +16727% | +145M shares |
| 5 years | +34737% | +145M shares |
CHRN has 145M diluted shares, up 8489% from a year ago.
ASTS Net Leverage
ASTS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CHRN Net Leverage
CHRN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ASTS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 11.9 | Oversold |
ASTS's weekly RSI is 34 (neutral) and its Stochastic is 12 (oversold).
CHRN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.3 | Neutral |
| Stochastic | 8.3 | Oversold |
CHRN's weekly RSI is 37 (neutral) and its Stochastic is 8 (oversold).
ASTS PE vs Technology Sector
ASTS has no meaningful PE right now: it lost money over the past year.
CHRN PE vs Technology Sector
CHRN has no meaningful PE right now: it lost money over the past year.
ASTS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $44.9 | 23% below |
| 20 week MA | $57.1 | 40% below |
| 50 week MA | $75.5 | 54% below |
| 100 week MA | $57.8 | 40% below |
| 200 week MA | $33.6 | 2.8% above |
ASTS has fallen below most of its moving averages, though it's still 2.8% above its 200-week average.
CHRN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $15.4 | 30% below |
| 20 week MA | $18.8 | 42% below |
| 50 week MA | $14.5 | 25% below |
| 100 week MA | $10.1 | 7.5% above |
| 200 week MA | $14.9 | 27% below |
CHRN's trend is mixed: it's above one of its five weekly moving averages, and 27% below its 200-week average.
ASTS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.87 | $13.4 | +36% |
| 2021 | $13.4 | $8.71 | -35% |
| 2022 | $8.71 | $3.97 | -54% |
| 2023 | $3.97 | $6.03 | +52% |
| 2024 | $6.03 | $22.9 | +280% |
| 2025 | $22.9 | $72.0 | +214% |
| 2026 YTD | $72.0 | $34.5 | -52% |
ASTS's yearly returns have swung widely, from +280% in 2024 to −54% in 2022. It's down 52% so far in 2026.
CHRN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $78.8 | $104.7 | +33% |
| 2021 | $104.7 | $45.3 | -57% |
| 2022 | $45.3 | $18.6 | -59% |
| 2023 | $18.6 | $37.5 | +102% |
| 2024 | $37.5 | $9.74 | -74% |
| 2025 | $9.74 | $5.56 | -43% |
| 2026 YTD | $5.56 | $10.9 | +95% |
CHRN has the edge over ASTS on returns for 2026, with the stronger performance.